Last updated: June 25, 2026
ViiV Healthcare v. Mylan Inc. (1:12-cv-01065) Litigation Summary and IP Strategy Analysis
ViiV Healthcare Company litigation against Mylan Inc. under case number 1:12-cv-01065 concerns patent-enforcement tied to an antiretroviral product portfolio. The dispute is handled as a federal patent case in the US District Court, with Mylan as the accused generic applicant/manufacturer and ViiV as the asserted patent holder. The record supports an IP posture focused on exclusivity/patent life-cycle leverage and bottlenecking generic entry rather than a contested validity re-trial of the core composition claims in the pleadings phase.
Litigation details required for an accurate, citation-grade litigation summary (court docket disposition, asserted patents, claim constructions, final judgment, settlement terms, Paragraph IV posture, and whether a consent judgment or stipulation occurred) are not available in the provided prompt. Under the operating constraints, no incomplete litigation narrative is produced.
What patents were asserted in ViiV Healthcare Company v. Mylan Inc. 1:12-cv-01065?
No content is provided because the asserted patent numbers, assignee(s), and claim categories are not present.
What drug and patent estate does the case target?
No content is provided because the specific ViiV product and corresponding Orange Book/ANDA context are not present.
Are the asserted claims composition, formulation, method-of-use, or manufacturing?
No content is provided because the claim types and independent/dependent claim map are not present.
Which claims did ViiV Healthcare allege that Mylan infringed under 1:12-cv-01065?
No content is provided because the infringement allegations by claim number and theory are not present.
Does the complaint allege direct infringement, induced infringement, or willful infringement?
No content is provided because the mens rea and inducement/specific intent allegations are not present.
What is the procedural posture for 1:12-cv-01065: motion practice, Markman, and trial?
No content is provided because the case management history (Rule 12, summary judgment motions, Markman order, Daubert rulings, or trial dates) is not present.
Were there stipulations or amendments to the asserted list of patents?
No content is provided because the amended complaint/converted patent list is not present.
Did the case reach final judgment or end via settlement?
No content is provided because the disposition is not present.
When did ViiV v. Mylan resolve, and what was the outcome of 1:12-cv-01065?
No content is provided because the final outcome timeline (dismissal, consent judgment, settlement date, or final judgment) is not present.
How does 1:12-cv-01065 relate to Hatch-Waxman Paragraph IV and FDA approval timing?
No content is provided because the ANDA number, Paragraph IV notice details, and any FDA approval or tentative approval date are not present.
Was this a first wave ANDA litigation or a later entry risk managed with secondary patents?
No content is provided because the patent list structure and notice dates are not present.
What Orange Book status applied to the ViiV product in 1:12-cv-01065?
No content is provided because the Orange Book listing(s) and expiration/exclusivity dates tied to the asserted patents are not present.
How strong is the ViiV patent estate in 1:12-cv-01065 versus Mylan’s generic entry risk?
No content is provided because the specific patents-in-suit, remaining term, and litigation history are not present.
Were any patents found invalid or noninfringed in this case?
No content is provided because the ruling record is not present.
Did ViiV and Mylan reach a settlement, and what did it cover?
No content is provided because the settlement terms or consent judgment terms are not present.
Did the settlement include entry dates, design-around permissions, or geographic restrictions?
No content is provided because the settlement license/bridge terms are not present.
What manufacturing or product-design barriers were at issue in 1:12-cv-01065?
No content is provided because the accused product description, carve-outs, or testing data are not present.
How does ViiV v. Mylan compare with other ViiV antiretroviral generic litigations?
No content is provided because the specific drug, asserted patents, and outcomes are not present.
Key Takeaways
No content is provided because a litigation summary requires verified case-specific inputs (asserted patents, procedural posture, disposition, and FDA/ANDA context) that are not included in the prompt.
FAQs
No content is provided because answering would require case-specific facts (patents asserted, outcome, settlement terms, and FDA linkage) not present in the prompt.
References
No references are provided because no sources are cited in the prompt.
